Eye Health News and Research

Latest Eye Health News and Research

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Beaver Medical Group is expanding the range of ophthalmological services offered at its Banning Specialty Care Center. By relocating the SCC ophthalmology services within the facility and purchasing new technology, patients will have greater access and more convenience when they need eye care.

17 Aug 2010

Non-viral gene therapy delays onset of eye disease

In one of only two studies of its kind, a study from researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts demonstrates that non-viral gene therapy can delay the onset of some forms of eye disease and preserve vision. The team developed nanoparticles to deliver therapeutic genes to the retina and found that treated mice temporarily retained more eyesight than controls.

17 Aug 2010

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

A new study describes how a carbohydrate-binding protein, galectin-3, promotes angiogenesis, the growth of new blood vessels. Targeting the protein, scientists identified two approaches that significantly reduced angiogenesis in mice. These discoveries, published online August 16 in The Journal of Experimental Medicine, may lead to novel treatments for diseases caused by excessive angiogenesis, including age-related macular degeneration, cancer, and diabetes.

16 Aug 2010

Today's Opinions: Challenges for independent Medicare board; Lack of independent analysis of Medicare finances; Medical schools shouldn't fear restrictions on ties to industry

One of the most promising aspects of the new health-care reform is the creation of an independent board to recommend changes in federal health programs and a fast-track provision that would allow these changes to take effect automatically unless Congress comes up with alternatives that would save a similar amount (8/16).

16 Aug 2010

NeoStem second-quarter revenues increase 26% to $19.4 million

NeoStem, Inc. an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units, U.S. adult stem cells, China adult stem cells, and China pharmaceuticals is today providing results of its second quarter 2010.

16 Aug 2010

August is National Immunization and Cataract Awareness Month

Childhood immunizations keep our children safe from a number of serious diseases. This is a good time of year to make sure your child is up-to-date on all of his/her immunizations. Continue reading to find out which vaccines the Centers for Disease Control and Prevention (CDC) recommend for children 6 and under.

16 Aug 2010

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

The easy accessibility of the eye and the established link between specific genetic defects and ocular disorders offer hope for using gene therapy to provide long-term therapeutic benefit. Two reports in the current issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc., describe the effective replacement of a human gene to preserve photoreceptor function in a mouse model of severe retinal degeneration. The articles are available free online.

16 Aug 2010

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced completion of a $13 million Series C financing. Existing investors Perseus Soros Biopharmaceutical Fund, L Capital Partners and Pappas Ventures all participated in the financing. CeNeRx plans to use the proceeds to conduct a Phase II trial of its improved formulation of its novel antidepressant TriRima™.

13 Aug 2010

AHRQ selects Outcome Sciences to study effects of different treatments for open angle glaucoma

Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.

13 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Today's Opinions: Health law's effect for Democrats; Canadians' view; Cutting Medicare costs; The health issue in Tenn. Governor's race

Despite lofty predictions that a broad-based Democratic constituency would be activated by the health care reform bill, recent polling shows that the bill has been a disaster for the party — with near 60 percent of voters saying that they oppose the measure (Douglas Schoen, 8/11).

13 Aug 2010

Survey finds high level of noncompliance with PPE protocols among safety professionals

Nearly all of the safety professionals in a survey released today said that workers in their organizations had at some point failed to wear the necessary safety equipment while on the job. An exceedingly high 98 percent of respondents who attended the recent American Society of Safety Engineers (ASSE) show in Baltimore answered "yes" when asked if they had observed workers not wearing safety equipment when they should have been, according to the survey, which was conducted by Kimberly-Clark Professional.

12 Aug 2010

In-car coach has strongest effect on drivers prone to distraction: Research

Although many states have banned using handheld cell phones at the wheel, a ban is difficult to enforce, and doesn't cover the growing number of gadgets now available.

12 Aug 2010

Scientists develop new imaging technique to create three-dimensional images of melanoma

Melanoma is one of the less common types of skin cancer but it accounts for the majority of the skin cancer deaths (about 75 percent).The five-year survival rate for early stage melanoma is very high (98 percent), but the rate drops precipitously if the cancer is detected late or there is recurrence.So a great deal rides on the accuracy of the initial surgery, where the goal is to remove as little tissue as possible while obtaining "clean margins" all around the tumor.So far no imaging technique has been up to the task of defining the melanoma's boundaries accurately enough to guide surgery.Instead surgeons tend to cut well beyond the visible margins of the lesion in order to be certain they remove all the malignant tissue.Two scientists at Washington University in St. Louis have developed technologies that together promise to solve this difficult problem.

12 Aug 2010

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, a charitable corporation of Massachusetts and an affiliate of Harvard Medical School.

12 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

Survey finds prevalence of diabetic retinopathy high among U.S. adults

Nearly 30 percent of U.S. adults with diabetes over the age of 40 are estimated to have diabetic retinopathy, with about 4 percent of this population having vision-threatening retinopathy, according to a study in the August 11 issue of JAMA.

11 Aug 2010

OptiMedica to sell retina and glaucoma assets to Topcon

Global ophthalmic device company OptiMedica Corp. has announced that it has signed a definitive agreement to sell its retina and glaucoma assets to Topcon Corp., a strategic move that positions OptiMedica to focus exclusively on the continued development and commercialization of advanced technologies for the treatment of cataract.

11 Aug 2010

Eye Health News and Research

Latest Eye Health News and Research

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Non-viral gene therapy delays onset of eye disease

Study reveals how galectin-3 carbohydrate-binding protein promotes angiogenesis

Today's Opinions: Challenges for independent Medicare board; Lack of independent analysis of Medicare finances; Medical schools shouldn't fear restrictions on ties to industry

NeoStem second-quarter revenues increase 26% to $19.4 million

August is National Immunization and Cataract Awareness Month

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

CeNeRx BioPharma raises $13 million through Series C financing to support TriRima Phase II trial

AHRQ selects Outcome Sciences to study effects of different treatments for open angle glaucoma

NovaBay second-quarter net loss increases to $1.2 million

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Today's Opinions: Health law's effect for Democrats; Canadians' view; Cutting Medicare costs; The health issue in Tenn. Governor's race

Survey finds high level of noncompliance with PPE protocols among safety professionals

In-car coach has strongest effect on drivers prone to distraction: Research

Scientists develop new imaging technique to create three-dimensional images of melanoma

NeoStem, Schepens Eye Research Institute collaborate to develop therapies for AMD and Glaucoma

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

Survey finds prevalence of diabetic retinopathy high among U.S. adults

OptiMedica to sell retina and glaucoma assets to Topcon

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Eye Health News and Research

Latest Eye Health News and Research

Genetics & Genomics - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in